For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Retatrutide

Also known as: Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)

Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).

Real-time market data

Pricing for Retatrutide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$7.19/mg

range $1.00–$33.68/mg

Sellers

80

from $0.00

45-day trend

-5.2%

vs 45-day avg $/mg

72 of 80 sellers have a current price· 49 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Retatrutide

429 third-party tests across 43 vendors. Each card links to the full report.

All 429 COAs for Retatrutide →
Measured purity 98.5%–100.0% across 247 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.99 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by NG Peptide· batch RT20-09

Aggregated · 3rd-party listing
99.86 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Aspire Peptides· batch RT20-032026-1

Aggregated · 3rd-party listing
99.78 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Aspire Peptides· batch RT15-032026-1

Aggregated · 3rd-party listing
99.72 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Aspire Peptides· batch GLP-3R

Aggregated · 3rd-party listing
99.28 %
Jul 2026
Janoshik Analytical Limited

For

Retatrutide

by EZ Peptides· batch EZP-3P1206222026-03

✓ Vendor-published
99.78 %
Jul 2026
Kovera Labs

For

Retatrutide

by Peptide Partners· batch RTT2613

COA on file
✓ Vendor-published
99.28 %
Jul 2026
Janoshik Analytical Limited

For

Retatrutide

by EZ Peptides· batch EZP-3P1206222026-03

COA on file
Aggregated · 3rd-party listing
99.81 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Virtus Peptides· batch RT30-655

Aggregated · 3rd-party listing
99.62 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Virtus Peptides· batch RT10-655

Aggregated · 3rd-party listing
98.71 %
Jul 2026
Janoshik Analytical Limited

For

Retatrutide

by Optima Supply· batch OS-2026-1258

Aggregated · 3rd-party listing
98.71 %
Jul 2026
Janoshik Analytical Limited

For

Retatrutide

by Hydro Research Peptides· batch HR-2026-2051

Aggregated · 3rd-party listing
99.82 %
Jun 2026
Freedom Diagnostics Moderate

For

Retatrutide

by Profound Aminos· batch White Cap

Aggregated · 3rd-party listing
99.94 %
Jun 2026
ILS Labs Strong

For

Retatrutide

by NG Peptide· batch rt30-6174

Aggregated · 3rd-party listing
99.69 %
Jun 2026
ILS Labs Strong

For

Retatrutide

by Forge Performance Co.· batch Clear Blue Cap

Aggregated · 3rd-party listing
99.65 %
Jun 2026
Janoshik Analytical Limited

For

Retatrutide

by EZ Peptides· batch EZP-3P2005222026-02

Aggregated · 3rd-party listing
99.65 %
Jun 2026
Janoshik Analytical Limited

For

Retatrutide

by EZ Peptides· batch EZP-3P2005222026-02

✓ Vendor-published
99.65 %
Jun 2026
Janoshik Analytical Limited

For

Retatrutide

by EZ Peptides· batch EZP-3P2005222026-02

COA on file
✓ Vendor-published
99.65 %
Jun 2026
Janoshik Analytical Limited

For

Retatrutide

by EZ Peptides· batch EZP-3P2005220226-02

COA on file
Aggregated · 3rd-party listing
99.84 %
Jun 2026
ILS Labs Strong

For

Retatrutide

by Peptide Plugs· batch 126-01-SM

Aggregated · 3rd-party listing
99.57 %
Jun 2026
ILS Labs Strong

For

Retatrutide

by Peptide Plugs· batch 129-01-DK

Aggregated · 3rd-party listing
99.56 %
Jun 2026
ILS Labs Strong

For

Retatrutide

by Peptide Plugs· batch 124-03-SM

Aggregated · 3rd-party listing
99.14 %
Jun 2026
ILS Labs Strong

For

Retatrutide

by NG Peptide· batch RT10-17

✓ Vendor-published
99.92 %
Jun 2026
TrustPointe Analytics Moderate

For

Retatrutide

by Peptide Partners· batch SPL-4092

COA on file
Aggregated · 3rd-party listing
99.78 %
Jun 2026
ILS Labs Strong

For

Retatrutide

by Voltera Sciences· batch RT60.05.28.26

Research depth

23 citations indexed for Retatrutide

All research on Retatrutide →

animal · 2026

Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats

Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling.

review · 2026

Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Introduction It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile.

rct · 2026

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Background Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications.

Study · 2026

A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide

Retatrutide is a novel triple agonist that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R).

Study · 2026

Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes

Context In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D. Objective Assess plasma metabolome and lipidome changes associated with retatrutide treatment.

Study · 2026

Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease

Background and hypothesis Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D).